A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Nivolumab (Primary) ; Visugromab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms GDFather-Neo; NEO-GDFATHER
- Sponsors CatalYm
Most Recent Events
- 02 Apr 2025 Planned End Date changed from 30 Apr 2026 to 30 Sep 2026.
- 02 Apr 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Aug 2025.
- 02 Apr 2025 Status changed from recruiting to active, no longer recruiting.